Precigen, Inc. announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.38 USD | -1.43% | +8.66% | +2.99% |
May. 14 | Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 14 | Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.99% | 348M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- PGEN Stock
- News Precigen, Inc.
- Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy